405 related articles for article (PubMed ID: 22253393)
1. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
Angiolillo DJ; Firstenberg MS; Price MJ; Tummala PE; Hutyra M; Welsby IJ; Voeltz MD; Chandna H; Ramaiah C; Brtko M; Cannon L; Dyke C; Liu T; Montalescot G; Manoukian SV; Prats J; Topol EJ;
JAMA; 2012 Jan; 307(3):265-74. PubMed ID: 22253393
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.
Firstenberg MS; Dyke CM; Angiolillo DJ; Ramaiahm C; Price M; Brtko M; Welsby I; Chandna H; Holmes DR; Voeltz M; Tummala P; Hutyra M; Manoukian SV; Prats J; Todd M; Liu T; Chronos N; Dietrich M; Montalescot G; Cannon LA; Topo EJ
Heart Surg Forum; 2013 Apr; 16(2):E60-9. PubMed ID: 23625478
[TBL] [Abstract][Full Text] [Related]
3. Cangrelor in patients undergoing cardiac surgery: the BRIDGE study.
Voeltz MD; Manoukian SV
Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):811-6. PubMed ID: 23895024
[TBL] [Abstract][Full Text] [Related]
4. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
[TBL] [Abstract][Full Text] [Related]
5. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL
JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833
[TBL] [Abstract][Full Text] [Related]
7. Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Bhatt DL; Stone GW; Mahaffey KW; Gibson CM; Steg PG; Hamm CW; Price MJ; Leonardi S; Gallup D; Bramucci E; Radke PW; Widimský P; Tousek F; Tauth J; Spriggs D; McLaurin BT; Angiolillo DJ; Généreux P; Liu T; Prats J; Todd M; Skerjanec S; White HD; Harrington RA;
N Engl J Med; 2013 Apr; 368(14):1303-13. PubMed ID: 23473369
[TBL] [Abstract][Full Text] [Related]
8. Intravenous platelet blockade with cangrelor during PCI.
Bhatt DL; Lincoff AM; Gibson CM; Stone GW; McNulty S; Montalescot G; Kleiman NS; Goodman SG; White HD; Mahaffey KW; Pollack CV; Manoukian SV; Widimsky P; Chew DP; Cura F; Manukov I; Tousek F; Jafar MZ; Arneja J; Skerjanec S; Harrington RA;
N Engl J Med; 2009 Dec; 361(24):2330-41. PubMed ID: 19915222
[TBL] [Abstract][Full Text] [Related]
9. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Gutierrez JA; Harrington RA; Blankenship JC; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Généreux P; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
Eur Heart J; 2016 Apr; 37(14):1122-30. PubMed ID: 26400827
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry.
Nakamura M; Kadota K; Takahashi A; Kanda J; Anzai H; Ishii Y; Shibata Y; Yasaka Y; Takamisawa I; Yamaguchi J; Takeda Y; Harada A; Motohashi T; Iijima R; Uemura S; Murakami Y;
J Am Heart Assoc; 2020 May; 9(10):e015439. PubMed ID: 32394794
[TBL] [Abstract][Full Text] [Related]
11. Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy?
Mahla E; Prueller F; Farzi S; Pregartner G; Raggam RB; Beran E; Toller W; Berghold A; Tantry US; Gurbel PA
Ann Thorac Surg; 2016 Dec; 102(6):2010-2017. PubMed ID: 27378554
[TBL] [Abstract][Full Text] [Related]
12. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
Cavender MA; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Deliargyris EN; Prats J; Mahaffey KW; White HD; Bhatt DL;
Circ Cardiovasc Interv; 2022 Jan; 15(1):e010390. PubMed ID: 34915723
[TBL] [Abstract][Full Text] [Related]
13. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.
Peterson BE; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL
Circ Cardiovasc Interv; 2022 Mar; 15(3):e011069. PubMed ID: 35196863
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
Bowman S; Gass J; Weeks P
Ann Pharmacother; 2019 Feb; 53(2):171-177. PubMed ID: 30132336
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
[TBL] [Abstract][Full Text] [Related]
16. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Sawlani NN; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL
Circ Cardiovasc Interv; 2017 Jan; 10(1):. PubMed ID: 28039321
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.
O'Donoghue ML; Bhatt DL; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Liu T; Deliargyris EN; Mahaffey KW; White HD; Harrington RA;
Circulation; 2016 Jan; 133(3):248-55. PubMed ID: 26762525
[TBL] [Abstract][Full Text] [Related]
18. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.
Steg PG; Bhatt DL; Hamm CW; Stone GW; Gibson CM; Mahaffey KW; Leonardi S; Liu T; Skerjanec S; Day JR; Iwaoka RS; Stuckey TD; Gogia HS; Gruberg L; French WJ; White HD; Harrington RA;
Lancet; 2013 Dec; 382(9909):1981-92. PubMed ID: 24011551
[TBL] [Abstract][Full Text] [Related]
19. Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.
De Luca L; Steg PG; Bhatt DL; Capodanno D; Angiolillo DJ
J Am Heart Assoc; 2021 Jul; 10(13):e022125. PubMed ID: 34212768
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
Leonardi S; Mahaffey KW; White HD; Gibson CM; Stone GW; Steg GW; Hamm CW; Price MJ; Todd M; Dietrich M; Gallup D; Liu T; Skerjanec S; Harrington RA; Bhatt DL
Am Heart J; 2012 May; 163(5):768-776.e2. PubMed ID: 22607853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]